NDT Advance Access originally published online on August 31, 2004
Nephrology Dialysis Transplantation 2004 19(11):2778-2783; doi:10.1093/ndt/gfh485
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nephrol Dial Transplant Vol. 19 No. 11 © ERA-EDTA 2004; all rights reserved
Original Article
Acute interstitial nephritis: clinical features and response to corticosteroid therapy
1 Brigham and Women's Hospital, Renal Division, Boston, MA, USA, 2 Beaumont Hospital, Department of Nephrology and Transplantation and 3 Mater Misericordiae Hospital, Department of Medicine and Therapeutics, Dublin, Ireland
Correspondence and offprint requests to: Michael R. Clarkson, Renal Division, Brigham and Women's Hospital, 75 Frances Street, Boston, MA 02115, USA. Email: mrclarkson{at}partners.org
Background. Acute interstitial nephritis (AIN) is a recognized cause of reversible acute renal failure characterized by the presence of an interstitial inflammatory cell infiltrate.
Methods. In order to evaluate the clinical characteristics and management of this disorder, we performed a retrospective study of all cases of AIN found by reviewing 2598 native renal biopsies received at our institution over a 12 year period. Presenting clinical, laboratory and histological features were identified, as was clinical outcome with specific regard to corticosteroid therapy response.
Results. AIN was found in 2.6% of native biopsies, and 10.3% of all biopsies performed in the setting of acute renal failure during the period analysed (n = 60). The incidence of AIN increased progressively over the period observed from 1 to 4% per annum. AIN was drug related in 92% of cases and appeared to be idiopathic in the remainder. The presenting symptoms included oliguria (51%), arthralgia (45%), fever (30%), rash (21%) and loin pain (21%). Median serum creatinine at presentation was 670 µmol/l [interquartile range (IQR) 431–1031] and 58% of cases required acute renal replacement therapy. Corticosteroid therapy was administered in 60% of cases. Serum creatinine at baseline was similar in the corticosteroid-treated and conservatively managed groups; 700 µmol/l (IQR 449–1031) vs 545 µmol/l (IQR 339–1110) P = 0.4. In this, the largest retrospective series to date, we did not detect a statistically significant difference in outcome, as determined by serum creatinine, between those patients who received corticosteroid therapy and those who did not, at 1, 6 and 12 months following presentation.
Conclusion. The results of this study do not support the routine administration of corticosteroid therapy in the management of AIN.
Keywords: acute interstitial nephritis; acute renal failure; corticosteroids
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. T. Sinnamon, A. E. Courtney, C. Harron, D. M. O'Rourke, and R. N. Mullan Tubulointerstitial nephritis and uveitis (TINU) syndrome: epidemiology, diagnosis and management NDT Plus, April 1, 2008; 1(2): 112 - 116. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Izzedine, I. Brocheriou, O. Rixe, and G. Deray Interstitial nephritis in a patient taking sorafenib Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2411 - 2411. [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Preddie, G. S. Markowitz, J. Radhakrishnan, T. L. Nickolas, V. D. D'Agati, J. A. Schwimmer, M. Gardenswartz, R. Rosen, and G. B. Appel Mycophenolate Mofetil for the Treatment of Interstitial Nephritis Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 718 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rodriguez-Iturbe Is Mycophenolate Mofetil a New Treatment Option in Acute Interstitial Nephritis? Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 609 - 610. [Full Text] [PDF]
|
|